Open-label, Multiple-dose, Phase III Study of the Population Pharmacokinetics of I.V. Synercid in 75 Pediatric Patients

Stopped early · Phase 3

Conditions studied: Gram-Positive Bacterial Infections

In brief

Open-label, multicenter, multiple-dose, study of population pharmacokinetics of I.V. Synercid (7.5 mg/kg every 8 hours) in 75 pediatric patients. The purpose is to assess the population pharmacokinetics of Synercid in pediatric patients and to collect additional safety and efficacy data in pediatric patients.

Key facts

Study ID

NCT00240747

Run by

Pfizer

Starts

2000-06-01

Expected to finish

2005-01-01

Last updated by the study team

2012-05-25

Who can join

Age: 1 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Serious, suspected or documented gram-positive infection

Where it is running

• Children's Hospital — Oakland, California, United States
• Children's Hospital of Orange County — Orange, California, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Children's Hospital — Cincinnati, Ohio, United States
• The Cleveland Clinic — Cleveland, Ohio, United States
• Children's Hospital at Saint Francis — Tulsa, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.